Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The first quarter earnings results of Acadia Healthcare show steady financial growth, with total revenue increasing by 9.1% compared to the first quarter of the previous year, reaching $768 million.</li><li>The company attributes this growth to rate improvement and patient day growth, which have also contributed to a 14.9% EBITDA growth and a 12.0% growth in adjusted EPS. These results are also a result of the company's labor cost improvement efforts and the continued strategies around hiring, retention, and quality.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

The first quarter earnings results of Acadia Healthcare show steady financial growth, with total revenue increasing by 9.1% compared to the first quarter of the previous year, reaching $768 million.The company attributes this growth to rate improvement and patient day growth, which have also contributed to a 14.9% EBITDA growth and a 12.0% growth in adjusted EPS. These results are also a result of the company's labor cost improvement efforts and the continued strategies around hiring, retention, and quality.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Acadia Healthcare Company: How Are They  Capitalizing on Mergers & Acquisitions Opportunities? - Major Drivers

<ul><li>ACADIA Pharmaceuticals announced its fourth-quarter and full-year results for 2023.</li><li>The company's CEO, Steve Davis, stated that ACADIA had transformed its business in 2023 by becoming a cash flow positive company with two first-in-class commercial assets.</li><li>These assets include DAYBUE, a drug approved for treatment of Rett syndrome, and NUPLAZID, a treatment for Parkinson's disease psychosis.</li></ul>

ACADIA Pharmaceuticals announced its fourth-quarter and full-year results for 2023.The company's CEO, Steve Davis, stated that ACADIA had transformed its business in 2023 by becoming a cash flow positive company with two first-in-class commercial assets.These assets include DAYBUE, a drug approved for treatment of Rett syndrome, and NUPLAZID, a treatment for Parkinson's disease psychosis.

Acadia Healthcare: Initiation Of Coverage - Potential To Expand DAYBUE in International Markets Can Be A Game Changer! - Major Drivers

<ul><li>Acadia Healthcare delivered a robust financial performance for 2023, marked by a 12.2% annual revenue growth, 13.1% adjusted EBITDA growth, and 14.3% adjusted EPS growth compared to 2022.</li><li>In the fourth quarter, its same-facility revenue rose by 10.3% on the back of rate improvements and patient day growth.</li><li>Acadia also saw consistent improvement in its labor trends throughout 2023.</li></ul>

Acadia Healthcare delivered a robust financial performance for 2023, marked by a 12.2% annual revenue growth, 13.1% adjusted EBITDA growth, and 14.3% adjusted EPS growth compared to 2022.In the fourth quarter, its same-facility revenue rose by 10.3% on the back of rate improvements and patient day growth.Acadia also saw consistent improvement in its labor trends throughout 2023.

Acadia Healthcare Company Inc.: Initiation Of Coverage - Investment in technology to optimize infrastructure and clinical outcomes! - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Equities not yet out of the woods, but as long as SPX is above 4165-4200, most signs point to this being a normal pullback within the ongoing bullish SPX trend.</li>
<li>Similarly, the Nasdaq 100 (QQQ) is testing support at $350-$355 (the 4-month bull flag/falling wedge pattern). The Russell 2000 is also approaching 1+ year support at 1640.</li>
<li>Breakdowns would be our cue to get defensive, as it would likely lead to precipitous declines. However, if supports hold, this is where risk/reward is skewed in favor of buyers.</li>
</ul>


Equities not yet out of the woods, but as long as SPX is above 4165-4200, most signs point to this being a normal pullback within the ongoing bullish SPX trend.
Similarly, the Nasdaq 100 (QQQ) is testing support at $350-$355 (the 4-month bull flag/falling wedge pattern). The Russell 2000 is also approaching 1+ year support at 1640.
Breakdowns would be our cue to get defensive, as it would likely lead to precipitous declines. However, if supports hold, this is where risk/reward is skewed in favor of buyers.


S&P 500, Nasdaq 100 Back at Support; Downgrading Discretionary to Market, Materials to Underweight

High Quality Stock Setups, Weekly Stock Bull Finder

Weekly Stock Bull Finder

High Quality Stock Setups

Finding high potential stock setups on quality companies

Thematic (Sector/Industry)

<ul><li>An interesting dynamic has emerged over the past few months with mega cap technology companies like Meta, Alphabet, and Amazon all seeing considerable weakness while other pockets of the market have emerged to move higher. </li><li>The market has recently “shaken off” some pretty bad earnings reports from mega cap tech while other pockets of the market continue to see breakouts which is a notable character change from the past few years. </li><li>After seeing mega cap technology earnings results from this past week, some have questioned whether a new crop of market leadership is ready to take over the mantle from the big cap technology companies.</li></ul>

An interesting dynamic has emerged over the past few months with mega cap technology companies like Meta, Alphabet, and Amazon all seeing considerable weakness while other pockets of the market have emerged to move higher. The market has recently “shaken off” some pretty bad earnings reports from mega cap tech while other pockets of the market continue to see breakouts which is a notable character change from the past few years. After seeing mega cap technology earnings results from this past week, some have questioned whether a new crop of market leadership is ready to take over the mantle from the big cap technology companies.

United States

Acadia Healthcare Co Ltd operates a network of behavioral health centers. The Company provides psychiatric and chemical dependency services, inpatient psychiatric hospitals, residential treatment centers, outpatient clinics, and therapeutic school based programs across the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acadia Healthcare Co (ACHC US)

Acadia Healthcare Company: How Are They Capitalizing on Mergers & Acquisitions Opportunities? - Major Drivers

The first quarter earnings results of Acadia Healthcare show steady financial growth, with total revenue increasing by 9.1% compared to the first...

Baptista Research

Acadia Healthcare: Initiation Of Coverage - Potential To Expand DAYBUE in International Markets Can Be A Game Changer! - Major Drivers

ACADIA Pharmaceuticals announced its fourth-quarter and full-year results for 2023. The company's CEO, Steve Davis, stated that ACADIA had...

Baptista Research

Acadia Healthcare Company Inc.: Initiation Of Coverage - Investment in technology to optimize infrastructure and clinical outcomes! - Major Drivers

Acadia Healthcare delivered a robust financial performance for 2023, marked by a 12.2% annual revenue growth, 13.1% adjusted EBITDA growth, and...

Baptista Research

S&P 500, Nasdaq 100 Back at Support; Downgrading Discretionary to Market, Materials to Underweight

Unchanged outlook: equities not yet out of the woods, but as long as the $SPX is above 4165-4200, most signs point to this being a normal pullback....

Vermilion Research

Weekly Stock Bullfinder - Week of 10/31

An interesting dynamic has emerged over the past few months with mega cap technology companies like Meta, Alphabet, and Amazon all seeing...

Weekly Stock Bull Finder

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)